menu
    • menu
    [{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Climb Bio","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"CLYM116","moa":"APRIL","graph1":"Nephrology","graph2":"Preclinical","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Beijing Mabworks Biotech \/ Climb Bio","highestDevelopmentStatusID":"4","companyTruncated":"Beijing Mabworks Biotech \/ Climb Bio"}]

    Find Clinical Drug Pipeline Developments & Deals by Beijing Mabworks Biotech

    Menu

    Beijing Mabworks Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Beijing Mabworks Biotech

                            China arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Beijing Mabworks Biotech

                            China arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLYM116

                            Therapeutic Area : Nephrology

                            Study Phase : Preclinical

                            Sponsor : Climb Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Climb Bio Expands Pipeline with Antibody Targeting APRIL Pathway in IgA Nephropathy

                            Details : Under the licensing agreement, Climb Bio will hold the exclusive rights to develop and commercialize MIL116 (CLYM116), an anti-APRIL monoclonal antibody, in the territory outside of Greater China.

                            Product Name : MIL116

                            Product Type : Antibody

                            Upfront Cash : $9.0 million

                            January 09, 2025

                            Lead Product(s) : CLYM116

                            Therapeutic Area : Nephrology

                            Highest Development Status : Preclinical

                            Sponsor : Climb Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth